Viking Therapeutics Gains as Obesity Pipeline Momentum Builds

Viking Therapeutics (VKTX) is up 8.9% today. Here is some analysis on what might have caused this price movement.

Analysis: The rally appears to be driven by renewed optimism around Viking’s obesity pipeline rather than a single major same-day corporate announcement. Recent momentum includes the June launch of a Phase 1 study for VK3019, ongoing Phase 3 development for VK2735, and a fresh analyst reiteration highlighting upcoming maintenance-study data as a potential catalyst.

Details:

Viking recently started a Phase 1 single-ascending-dose study of VK3019, its amylin-based obesity candidate, expanding its weight-loss portfolio beyond VK2735.

The company’s lead obesity asset, VK2735, remains in the Phase 3 VANQUISH program, keeping investor focus on a late-stage development story in one of biotech’s hottest categories.

Additional oral VK2735 data presented in May showed dose-dependent weight loss through 13 weeks without an observed plateau, reinforcing enthusiasm for both injectable and tablet formulations.

An analyst note published today reiterated a bullish rating and pointed to third-quarter 2026 maintenance-study data for subcutaneous VK2735 as an underappreciated near-term catalyst.

Sources:

Viking Therapeutics, SEC, Investing.com

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$VKTX Insider Trading Activity

$VKTX insiders have traded $VKTX stock on the open market 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.

Here’s a breakdown of recent trading of $VKTX stock by insiders over the last 6 months:

NEIL WILLIAM AUBUCHON (Chief Commercial Officer) purchased 4,475 shares for an estimated $149,912

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

$VKTX Hedge Fund Activity

We have seen 177 institutional investors add shares of $VKTX stock to their portfolio, and 169 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

TWO SIGMA INVESTMENTS, LP added 1,996,405 shares (+82.0%) to their portfolio in Q1 2026, for an estimated $64,963,018
AMERICAN CENTURY COMPANIES INC added 1,773,211 shares (+580.7%) to their portfolio in Q1 2026, for an estimated $57,700,285
RAYMOND JAMES FINANCIAL INC added 1,153,405 shares (+125.1%) to their portfolio in Q1 2026, for an estimated $37,531,798
VESTAL POINT CAPITAL, LP added 914,147 shares (+inf%) to their portfolio in Q1 2026, for an estimated $29,746,343
JANE STREET GROUP, LLC removed 752,168 shares (-50.1%) from their portfolio in Q1 2026, for an estimated $24,475,546
SUSQUEHANNA INTERNATIONAL GROUP, LLP removed 718,022 shares (-50.4%) from their portfolio in Q1 2026, for an estimated $23,364,435
EXODUSPOINT CAPITAL MANAGEMENT, LP removed 652,572 shares (-90.4%) from their portfolio in Q1 2026, for an estimated $21,234,692

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$VKTX Price Targets

Multiple analysts have issued price targets for $VKTX recently. We have seen 4 analysts offer price targets for $VKTX in the last 6 months, with a median target of $101.0.

Here are some recent targets:

Daniel Brims from Lake Street set a target price of $89.0 on 05/28/2026
Jeet Mukherjee from BTIG set a target price of $125.0 on 05/01/2026
Steve Seedhouse from Cantor Fitzgerald set a target price of $100.0 on 04/30/2026
Joseph Pantginis from HC Wainwright & Co. set a target price of $102.0 on 03/23/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.